CBO: NIH budget cuts, slower FDA reviews would have significant impact on drug development
Regulatory NewsFerdous Al-Faruque
GenericsGovernment/legislationPharmaceuticalsRegulatory Intelligence/PolicyUnited StatesUS Food and Drug Administration (FDA)